Načítá se...
Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
Despite advances in the treatment of multiple myeloma, it remains an incurable disease, with relapses and resistances frequently observed. Recently, immunotherapies, in particular, monoclonal antibodies, have become important treatment options in anticancer therapies. Elotuzumab is a humanized monoc...
Uloženo v:
| Vydáno v: | Onco Targets Ther |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5063562/ https://ncbi.nlm.nih.gov/pubmed/27785050 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S94531 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|